ERBB2 and neoplasm: However, some case reports have established the role of chemotherapeutic agents (anthracyclines, taxanes, and platinum compounds), anti-HER-2-directed therapies, and endocrine therapies [17]. Currently, no data are describing the role of next-generation sequencing in metastatic apocrine cancers for the targeted therapies that may be related to tumor progression or drug resistance, as in recurrent/metastatic breast cancers proven to have additional genetic changes compared with the primary tumor [18].